ECSP10010599A - Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk) - Google Patents

Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)

Info

Publication number
ECSP10010599A
ECSP10010599A EC2010010599A ECSP10010599A ECSP10010599A EC SP10010599 A ECSP10010599 A EC SP10010599A EC 2010010599 A EC2010010599 A EC 2010010599A EC SP10010599 A ECSP10010599 A EC SP10010599A EC SP10010599 A ECSP10010599 A EC SP10010599A
Authority
EC
Ecuador
Prior art keywords
tienopiridon
ampk
derivatives
protein kinase
activated protein
Prior art date
Application number
EC2010010599A
Other languages
English (en)
Spanish (es)
Inventor
Christine Charon
Daniel Cravo
Sophie Hallakou-Bozec
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010599A publication Critical patent/ECSP10010599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EC2010010599A 2008-04-11 2010-11-09 Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk) ECSP10010599A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290364 2008-04-11

Publications (1)

Publication Number Publication Date
ECSP10010599A true ECSP10010599A (es) 2010-12-30

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010599A ECSP10010599A (es) 2008-04-11 2010-11-09 Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)

Country Status (25)

Country Link
US (1) US8563729B2 (enExample)
EP (1) EP2262500B1 (enExample)
JP (1) JP5592348B2 (enExample)
KR (1) KR101630466B1 (enExample)
CN (1) CN101998853B (enExample)
AU (1) AU2009235784B2 (enExample)
BR (1) BRPI0910439B8 (enExample)
CA (1) CA2721025C (enExample)
CO (1) CO6300954A2 (enExample)
DK (1) DK2262500T3 (enExample)
EA (1) EA017756B1 (enExample)
EC (1) ECSP10010599A (enExample)
ES (1) ES2584278T3 (enExample)
HR (1) HRP20160907T1 (enExample)
HU (1) HUE027857T2 (enExample)
IL (1) IL208067A (enExample)
MX (1) MX2010011047A (enExample)
MY (1) MY155836A (enExample)
NZ (1) NZ589136A (enExample)
PL (1) PL2262500T3 (enExample)
PT (1) PT2262500T (enExample)
SI (1) SI2262500T1 (enExample)
UA (1) UA103321C2 (enExample)
WO (1) WO2009124636A1 (enExample)
ZA (1) ZA201008050B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101648593B1 (ko) * 2008-05-05 2016-08-16 메르크 파텐트 게엠베하 Ａｍｐ-활성화된 단백질 키나아제 (ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체
PT2519527E (pt) 2009-12-29 2014-02-17 Poxel Tieno[2,3-b]piridinodiona como activadores de ampk e suas utilizações terapêuticas
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011121109A1 (en) 2010-04-02 2011-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012028582A1 (de) 2010-09-01 2012-03-08 Bayer Cropscience Ag Herbizid wirksame ketosultame und diketopyridine
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) * 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
CN108463218A (zh) 2015-09-30 2018-08-28 药物分子研究所 减弱寄生虫毒性的方法
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
KR102663976B1 (ko) * 2018-11-16 2024-05-09 폭셀 에스아 티에노피리돈 유도체의 1수화물 칼륨염 및 이의 제조 방법
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
MX2022011938A (es) * 2020-03-26 2023-01-04 Poxel Uso de un derivado de tienopiridona en el tratamiento de la adrenoleucodistrofia o adrenomieloneuropatia.
KR20220163978A (ko) * 2020-04-02 2022-12-12 폭셀 상염색체 우성 다낭 신질환 (adpkd) 의 치료에서의 티에노피리돈 유도체의 용도
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
AU2022391025A1 (en) 2021-11-19 2024-06-06 The Brigham And Women's Hospital, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233641A (en) 1989-05-16 1992-07-28 Merrell Dow Pharma Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)

Also Published As

Publication number Publication date
ZA201008050B (en) 2011-07-27
WO2009124636A1 (en) 2009-10-15
PT2262500T (pt) 2016-08-16
AU2009235784A1 (en) 2009-10-15
JP5592348B2 (ja) 2014-09-17
US20110034505A1 (en) 2011-02-10
EP2262500B1 (en) 2016-04-27
KR101630466B1 (ko) 2016-06-14
CN101998853B (zh) 2015-02-11
KR20100137563A (ko) 2010-12-30
SI2262500T1 (sl) 2016-09-30
UA103321C2 (ru) 2013-10-10
BRPI0910439A2 (pt) 2015-09-29
US8563729B2 (en) 2013-10-22
CO6300954A2 (es) 2011-07-21
HUE027857T2 (en) 2016-11-28
AU2009235784B2 (en) 2013-09-19
NZ589136A (en) 2012-06-29
BRPI0910439B1 (pt) 2020-10-20
MX2010011047A (es) 2010-10-26
CN101998853A (zh) 2011-03-30
PL2262500T3 (pl) 2016-09-30
BRPI0910439B8 (pt) 2021-05-25
IL208067A0 (en) 2010-12-30
HK1155955A1 (en) 2012-06-01
JP2011516510A (ja) 2011-05-26
CA2721025C (en) 2016-07-26
EP2262500A1 (en) 2010-12-22
EA017756B1 (ru) 2013-02-28
EA201001585A1 (ru) 2011-06-30
ES2584278T3 (es) 2016-09-26
CA2721025A1 (en) 2009-10-15
HRP20160907T1 (hr) 2016-09-23
IL208067A (en) 2015-05-31
MY155836A (en) 2015-12-15
DK2262500T3 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
CR11359A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
UY30835A1 (es) 8-alquinilxantinas y derivados
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR11814A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists